GlobeNewswire Inc.··Ataibeckley Inc.AtaiBeckley's Oral MDMA Therapy Shows Promise in Social Anxiety, Outperforming Placebo
AtaiBeckley reports Phase 2a results for EMP-01 oral R-MDMA in social anxiety disorder, showing 49% responder rates and 38% symptom reduction versus 15% on placebo.
ATAIclinical trial resultssocial anxiety disorder